// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Outcomes at 6 months following NIV in adults with cystic fibrosis (CF): experience of a large UK centre

Giulia Spoletini - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

Use of NIV in cystic fibrosis: 10-year experience of a large adult CF centre

Giulia Spoletini - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

Determining resting heart rate in children using wearable activity monitors

Kunal Kapoor - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

1H and 129Xe MRI to detect functional and structural lung disease in sub-clinical cystic fibrosis

Laurie Smith - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

Do CT findings of Mycobacterium abscessus infection in patients with Cystic Fibrosis predict outcome?

Victoria Holt - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

How can gene-editing of human pluripotent stem cells help cystic fibrosis?

Sara Cuevas Ocana - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

Methadone hydrochloride

Concomitance of maternal asthma and preeclampsia and asthma risk in the offspring

Guo-Qiang Zhang - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Preeclampsia

N/A

Comorbidities, hypersensitivity and biomarkers in a real-world US nasal polyps population

Megan Scott - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Aspirin

Residential greenness and lung function in a prospective cohort of European adults: The ECRHS study

Iana Markevych - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Examination of the causal association between lung function and Alzheimer’s Disease: a Mendelian Randomization study

Daniel Higbee - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Late Breaking Abstract - Longitudinal associations of testosterone status with lung function decline in UK Biobank

Alexandra Lenoir - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Androgen Tear

Cardiometabolic impact and symptom profile of obstructivesleep apnea: does gender matter?

Sophia Schiza - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Maternal blood pressure throughout pregnancy, gestational hypertension, and preeclampsia and offspring asthma

Guo-Qiang Zhang - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pregnancy-Induced Hypertension

N/A

Cognitive Function in COPD and controls

Ayushman Gupta - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Risk charts of five-year mortality in COPD patients

Andreas Horner - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary arterial hypertension

N/A

Variation in “normal values” of forced vital capacity (FVC) and ratio of one-second Forced Expiratory Volume (FEV1)/FVC between 42 Burden of Obstructive Lung Disease (BOLD) sites

Peter Burney - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prevalence of chronic cough, patient characteristics and health outcomes among UK adults

Lorcan Mcgarvey - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Does 7-day working improve outcomes for COPD?

Philip Stone - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Does the COPD Best Practice Tariff improve patient outcomes?

Philip Stone - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Prognosis of COPD according to exacerbation history: a population-based cohort study

Shoaib Afzal - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Copyright © 2026. QuantiNova All rights reserved